An FDA advisory committee said Thursday that FDA should approve flibanserin with conditions. The drug, aimed at boosting low libido in women, was recommended for approval with an 18–6 vote. FDA has rejected the drug two times, asserting that the benefits were outweighed by potential adverse effects including fainting, nausea, dizziness, sleepiness, and low blood pressure. On Thursday, the committee described the drug benefit as only "moderate" or "marginal"; but most panel members said that, with proper warning labels, the drug should be made available for women. While manufacturer Sprout Pharmaceuticals presented results of a series of double-blind trials indicating that flibanserin worked better than a placebo, some committee members said that after adjusting the data to take the placebo effect into account, the drug helped many fewer women. Conditions that panelists recommended for the drug's approval include warning labels, an education program, and prescriber training and certification, expressing particular concern that flibanserin not be used with alcohol, with certain drugs, or by pregnant women.